Immunomodulation as a treatment strategy for genital herpes: Review of the evidence

International Immunopharmacology

Volumn 2, Issue 4, 2002, Pages 443-451

  Miller, R L ^a   Tomai, M A ^a   Harrison, C J ^b   Bernstein, D I ^c  

^a 3M COMPANY   (United States)

^b University of Louisville School of Medicine   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Acquired immune response; Herpes simplex virus (HSV); Immune response modifiers; Immunomodulation; Recurrent genital herpes; Resiquimod

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON; IMIQUIMOD; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; RESIQUIMOD; S 25059; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; B LYMPHOCYTE; CELL STIMULATION; CELLULAR IMMUNITY; CLINICAL TRIAL; CONDYLOMA; DENDRITIC CELL; DRUG ACTIVITY; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; GENITAL HERPES; GUINEA PIG; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOPHARMACOLOGY; IN VITRO STUDY; IN VIVO STUDY; INTERFERON PRODUCTION; MACROPHAGE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; TH1 CELL;

ADJUVANTS, IMMUNOLOGIC; AMINOQUINOLINES; ANIMALS; HERPES GENITALIS; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HUMANS; IMIDAZOLES; RECURRENCE;

EID: 0036181703     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(01)00184-9     Document Type: Article

References (55)

1. GH and public health
2. Herpes simplex virus type 2 in the United States, 1976 to 1994
3. Recurrences after oral and GH simplex virus infection. Influence of site of infection and viral type
4. Risk factors for the sexual transmission of genital herpes
5. Guidelines for treatment of sexually transmitted diseases
6. National guideline for the management of genital herpes
7. Recurrence and resistance patterns of herpes simplex virus following cessation of >6 years of chronic suppression with acyclovir
8. Aciclovir A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy
9. Prolonged continuous acyclovir treatment of normal adults with frequently recurring genital herpes simplex virus infection
10. Current recommendations for the treatment of genital herpes
11. Herpes simplex type 2 infections - An update
12. Treatment of primary herpes simplex virus infection in guinea pigs by imiquimod
13. Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection
14. Imiquimod applied topically: A novel immune response modifier and new class of drug
15. Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine
16. Cytokine induction by the immunomodulators imiquimod and S-27609
17. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463
18. A randomized, controlled, molecular study of Condolymata Acuminata clearance during treatment with imiquimod
19. Evaluation of herpes simplex virus vaccines in animals: The guinea pig vaginal model
20. Self-administered topical 5% imiquimod cream for external anogenital warts
21. Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum
22. Detection of human papillomavirus and response to topical 5% imiquimod in a case of stucco keratosis
23. Recalcitrant molluscum contagiosum in an HIV-afflicted male treated successfully with topical imiquimod
24. Imiquimod 5% cream in the treatment of Bowen's disease
25. Imiquimod: A novel treatment for lentigo maligna
26. Molecular mechanisms of B lymphocyte activation by the immune response modifier R-848
27. The immune response modifier resiquimod mimics CD40-induced B cell activation
28. Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848
29. Mechanism of action of imiquimod
30. Identification of genes induced by a macrophage activator, S-28463, using gene expression array analysis
31. Modulation of Th1 and Th2 cytokine production with the immune response modifiers R-848 and imiquimod
32. Immunomodulating and antiviral activities of the imidazoquinoline S-28463
33. The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells
34. Effect of a novel topical immunomodulator, S-28463, on keratinocyte cytokine gene expression and production
35. Treatment of experimental leishmaniasis immunomodulators imiquimod and S-28463: Efficacy and mode of action
36. CD28/B7 system of T cell costimulation
37. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation
38. Production of interferon-α/β by murine dendritic cell lines stimulated by virus and bacteria
39. High level IL-12 production by murine dendritic cells: Upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10
40. Imiquimod, a topical immune response modifier, induces migration of Langerhans' cells
41. The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes
42. The holy grail: Immune control of human herpes simplex virus infection and disease
43. Prospects for control of herpes simplex virus disease through immunization
44. Potential for immunotherapy in the treatment of herpesvirus infections
45. Adjuvant effects of imiquimod on a herpes simplex virus type 2 glycoprotein vaccine in guinea pigs
46. Effect of imiquimod as an adjuvant for immunotherapy of genital HSV in guinea pigs
47. Adjuvant activities of immune response modifier R-848: Comparison with CpG ODN
48. Posttherapy suppression of GH simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs
49. Role of mucosal immunity in herpes simplex virus infection
50. T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfections with herpes simplex virus type 2
51. CD8 CTL from GH simplex lesions: Recognition of viral tegument and immediate early proteins and lysis of infected cutaneous cells
52. Reduction of recurrent HSV disease using imiquimod alone or combined with a glycoprotein vaccine
53. Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment
54. Application of a topically applied immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: A pilot study